Experience with heat shock protein‐peptide complex 96 vaccine therapy in patients with indolent non‐Hodgkin lymphoma

The objective of this phase II trial was to investigate the safety and efficacy of autologous heat shock protein‐peptide complex 96 (HSPPC‐96) vaccines prepared from tumor specimens of patients with newly diagnosed or previously treated indolent non‐Hodgkin lymphoma (NHL).

[1]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[2]  S. Pizzo,et al.  Cutting Edge: CD91-Independent Cross-Presentation of GRP94(gp96)-Associated Peptides1 , 2002, The Journal of Immunology.

[3]  L. Raez,et al.  Heat shock protein-based cancer vaccines. , 2006, Hematology/oncology clinics of North America.

[4]  Jonathan J. Lewis,et al.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. K. Bright,et al.  Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. , 1994, Journal of immunology.

[6]  P. Srivastava,et al.  Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. , 2001, Methods in molecular biology.

[7]  P. Srivastava,et al.  CD91: a receptor for heat shock protein gp96 , 2000, Nature Immunology.

[8]  D. Maloney.  Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Srivastava,et al.  Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia , 2005, Clinical Cancer Research.

[10]  P. Srivastava,et al.  Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. , 1998, Immunity.

[11]  N. Gordon,et al.  The challenges of bringing autologous HSP-based vaccines to commercial reality. , 2004, Methods.

[12]  Jonathan J. Lewis,et al.  Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Czerwinski,et al.  Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.

[15]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[16]  R. Levy,et al.  Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.

[17]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[18]  Jeffrey E. Lee,et al.  Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma , 2010, Journal of Translational Medicine.

[19]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.